Mixed
GLP-1 RA treatment is associated with significant lean tissue (muscle) loss, with studies showing 14-40% of total weight loss being lean mass, necessitating interventions to preserve muscle.
While GLP-1 RAs are effective for weight loss, they also cause muscle loss (14-40% of total weight loss). To protect your strength and metabolism, it is crucial to consume adequate protein and engage in resistance exercise during treatment. This is especially important for older adults or those already at risk of muscle loss.
Available body composition data shows an excessive degree of lean tissue loss. Within the STEP 1 and SUSTAIN 8 trials there was 38.9% and 39.6% lean tissue loss of total weight loss... the SURMOUNT trial showed lower lean tissue loss (14.3%)
Why this rating
Based on body composition substudies of major RCTs, though the paper notes limitations in data availability.
Source
“From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of <scp>GLP</scp>‐1 receptor agonists in obesity management services
Adrian Brown et al. · Nutrition Bulletin · 2024
DOI 10.1111/nbu.12700
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide produce clinically significant weight loss (15-22.5%) and cardiovascular risk reduction, serving as a scalable pharmacological adjunct to lifestyle interventions.Strong
- Discontinuation of GLP-1 RA therapy is associated with significant weight regain, suggesting that these medications may need to be used as long-term maintenance treatments rather than short-term interventions.Good
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →